<DOC>
	<DOCNO>NCT01120184</DOCNO>
	<brief_summary>This randomize , 3-arm , multicentre , phase III study evaluate efficacy safety trastuzumab emtansine ( T-DM1 ) pertuzumab trastuzumab emtansine ( T-DM1 ) pertuzumab-placebo ( blind pertuzumab ) , versus combination trastuzumab ( Herceptin ) plus taxane ( docetaxel paclitaxel ) patient HER2-positive progressive recurrent locally advance previously untreated metastatic breast cancer . Patients randomize 1 3 treatment arm ( Arms A , B C ) . Arm A open-label , whereas Arms B C blind .</brief_summary>
	<brief_title>A Study Trastuzumab Emtansine ( T-DM1 ) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab Herceptin Plus Taxane Patients With Metastatic Breast Cancer ( MARIANNE )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult patient &gt; /=18 year age HER2positive breast cancer Histologically cytologically confirm adenocarcinoma breast locally recurrent metastatic disease , candidate chemotherapy . Patients locally advanced disease must recurrent progressive disease , must amenable resection curative intent . Patients must measurable and/or nonmeasurable disease must evaluable per RECIST 1.1 ECOG Performance Status 0 1 Adequate organ function determine laboratory result History prior ( ) chemotherapy metastatic breast cancer recurrent locally advance disease An interval &lt; 6 month last dose vincaalkaloid taxane cytotoxic chemotherapy time metastatic diagnosis Hormone therapy &lt; 7 day prior randomization Trastuzumab therapy and/or lapatinib ( neo adjuvant set ) &lt; 21 day prior randomization Prior trastuzumab emtansine pertuzumab therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>